Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Maravai Lifesciences Holdings (MRVI)
NASDAQ:MRVI
RESEARCH TOOLSreports
Holding MRVI?
Track your performance easily
MRVI Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$4.28 - $11.56
Previous Close$5.43
Volume2.47M
Average Volume (3M)1.77M
Market Cap
$1.37B
Enterprise Value$1.61B
Total Cash (Recent Filing)$578.16M
Total Debt (Recent Filing)$553.80M
Price to Earnings (P/E)―
Beta1.24
Next Earnings
Feb 19, 2025EPS Estimate
-$0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.65
Shares Outstanding252,527,585
10 Day Avg. Volume1,574,721
30 Day Avg. Volume1,766,709
Standard Deviation0.17
R-Squared0.00042
Alpha-0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)3.92
Price to Sales (P/S)4.95
Price to Cash Flow (P/CF)26.10
P/FCF Ratio20.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.83
Enterprise Value/Gross Profit11.52
Enterprise Value/Ebitda-13.23
Forecast
1Y Price Target
$9.00Price Target Upside67.60% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
Maravai Lifesciences Holdings News
PremiumCompany Announcements
Maravai LifeSciences Appoints New Chairman Amid Leadership Transition
Bulls Say, Bears Say
Bulls Say
Financial PerformanceMaravai has delivered top-line beats for 3 consecutive quarters and remains on track for 2024 revenue targets.
Product LaunchesMRVI has launched 21 new products, including custom plate-based mRNA products and CleanScribe RNA polymerase, with positive customer feedback since launch.
Strategic CollaborationsNew Hopkins collaboration on mRNA Innovation Center should further drive adoption over time.
Bears Say
EarningsMRVI reported 3Q results below expectations, with both segments light vs. the model.
Financial PerformanceManagement reduced 2024 adjusted EBITDA margin by roughly 400 basis points at the midpoint, attributed to lower projected revenue from higher-margin areas.
Future OutlookPatience required to unlock meaningful upside given lack of visibility on macro recovery and relatively nascent mRNA pipeline.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
MRVI FAQ
What was Maravai Lifesciences Holdings’s price range in the past 12 months?
Maravai Lifesciences Holdings lowest stock price was $4.28 and its highest was $11.55 in the past 12 months.
What is Maravai Lifesciences Holdings’s market cap?
Currently, no data Available
When is Maravai Lifesciences Holdings’s upcoming earnings report date?
Maravai Lifesciences Holdings’s upcoming earnings report date is Feb 19, 2025 which is in 58 days.
How were Maravai Lifesciences Holdings’s earnings last quarter?
Maravai Lifesciences Holdings released its earnings results on Nov 07, 2024. The company reported -$0.02 earnings per share for the quarter, missing the consensus estimate of -$0.008 by -$0.012.
Is Maravai Lifesciences Holdings overvalued?
According to Wall Street analysts Maravai Lifesciences Holdings’s price is currently Undervalued.
Does Maravai Lifesciences Holdings pay dividends?
Maravai Lifesciences Holdings does not currently pay dividends.
What is Maravai Lifesciences Holdings’s EPS estimate?
Maravai Lifesciences Holdings’s EPS estimate is -$0.04.
How many shares outstanding does Maravai Lifesciences Holdings have?
Maravai Lifesciences Holdings has 141,843,500 shares outstanding.
What happened to Maravai Lifesciences Holdings’s price movement after its last earnings report?
Maravai Lifesciences Holdings reported an EPS of -$0.02 in its last earnings report, missing expectations of -$0.008. Following the earnings report the stock price went down -35.204%.
Which hedge fund is a major shareholder of Maravai Lifesciences Holdings?
Among the largest hedge funds holding Maravai Lifesciences Holdings’s share is Royce & Associates LLC. It holds Maravai Lifesciences Holdings’s shares valued at 8M.
---
Maravai Lifesciences Holdings Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.00 (67.60% Upside)
$9.00 (67.60% Upside)
Blogger Sentiment
Bearish
MRVI Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 408.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 5.2%
Last 30 Days ▼ 5.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-17.47%
12-Months-Change
Fundamentals
Return on Equity
-51.98%
Trailing 12-Months
Asset Growth
-43.63%
Trailing 12-Months
Company Description
Maravai Lifesciences Holdings
Maravai LifeSciences Holdings Inc is a life sciences company. It provides products to enable the development of drug therapies, diagnostics, novel vaccines and support research on human diseases. The company's segments are Nucleic acid production, Biologics safety testing, and Protein detection. It generates a majority of its revenue from the Nucleic Acid Production that focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.
---
MRVI Company Deck
---
MRVI Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed outlook with notable achievements in innovation and strategic acquisitions, but faced challenges in revenue shortfalls, market softness, and a significant goodwill impairment charge. The company's strong cash position and commitment to innovation are positive, but the financial pressures and revised guidance indicate ongoing challenges.Read More>---
MRVI Revenue Breakdown
77.79% Nucleic Acid Production
22.21% Biologics Safety Testing
---
MRVI Stock 12 Month Forecast
Average Price Target
$9.00
▲(67.60% Upside)
Technical Analysis
Best Analysts Covering MRVI
1 Year
1 Year Success Rate
3/13 ratings generated profit
1 Year Average Return
-25.92%
reiterated a buy rating 5 months ago
Copying Daniel Arias's trades and holding each position for 1 Year would result in 23.08% of your transactions generating a profit, with an average return of -25.92% per trade.
---